MarginsXMarginsX
Home › Markets › Health Care › AQST

Aquestive Therapeutics Inc. (AQST)

AQST trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.76
-3.84% on the day
Market cap
$472.6M
Small cap
Revenue · 2025
$44.5M
-22.6% on 2024
Net income · 2025
-$83.8M
-188.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/0001398733-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAQST on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001398733
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$44.5M
Net income-$83.8M
Operating income-$71.1M
Net margin-188.1%
Operating margin-159.5%
Revenue growth-22.6%
Cash$121.2M
Total assets$160.4M
P/E (computed)Net income was not positive
P/S (computed)10.6×

Warning signs

Cash runway
27.3 months
$90.3M cash at September 30, 2026
Share count, 1 year
+3.0%
2025-11-03 to 2026-10-30 · +88.2% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$3.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$90.3M cash; operating cash flow -$9.9M a quarter.Report 2026-09-30
Shares outstanding125,687,705 (2026-10-30); 122,003,113 a year earlier; 66,767,283 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Short Hills, New Jersey, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $3.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$7.6M-$16.5M-$7.0M$90.3M$55.0M$48.8M10-Q 2026-11-03
Q2 2026
2026-06-30
$13.8M-$22.9M-$9.4M$98.5M$55.0M$54.1M10-Q 2026-08-11
Q1 2026
2026-03-31
$14.4M-$8.1M-$14.8M$110.7M$45.0M$50.3M10-Q 2026-05-13
Q4 2025
2025-12-31
$13.0M-$31.9M-$8.5M$121.2M$45.0M$44.5M10-K 2026-03-04
Q3 2025
2025-09-30
$12.8M-$15.4M-$12.6M$129.1M$45.0M$43.4M10-Q 2026-11-03
Q2 2025
2025-06-30
$10.0M-$13.5M-$7.9M$60.5M$45.0M$44.1M10-Q 2026-08-11
Q1 2025
2025-03-31
$8.7M-$22.9M-$23.4M$68.7M$45.0M$54.2M10-Q 2026-05-13
Q4 2024
2024-12-31
$11.9M-$17.1M-$6.5M$71.5M$45.0M$57.6M10-K 2026-03-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-07-09
Latest annual report10-K2026-03-04
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 692 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+8.3%
1 month-16.3%
3 months-8.0%
Year to date-39.5%
1 year-26.2%
From 52-week high-40.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
STTKShattuck Labs Inc.$4.66+0.21%$474.6M
OCSOculis Holding AG$7.63-0.13%$469.9M
LYELLyell Immunopharma Inc.$14.65+2.45%$469.0M
KMDAKamada Ltd.$8.11+0.25%$468.0M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
NGNENeurogene Inc. Common Stock$23.30-2.63%$482.3M
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M
MNPRMonopar Therapeutics Inc.$71.97-0.04%$487.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier